Keratin 10 antibody

Catalog No. ABIN5707750

This anti-Keratin 10 antibody is a Rabbit Monoclonal antibody detecting Keratin 10 in IHC (p). Suitable for Human and Mouse.

Quick Overview for Keratin 10 antibody (ABIN5707750)

Target: Keratin 10 (KRT10)

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Monoclonal

Conjugate: This Keratin 10 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: KRT10-1990R

Product Details anti-Keratin 10 Antibody

Purification: Purified

Purity: Protein A affinity chromatography

Immunogen: Skin extract from a Psoriasis patient was used as the immunogen for the recombinant Cytokeratin 10 antibody.

Isotype: IgG kappa

Application Details

Application Notes: Optimal dilution of the recombinant Cytokeratin 10 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Immunohistochemistry (FFPE): 0.1-0.2 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

Restrictions: For Research Use only

Handling

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant Cytokeratin 10 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for Keratin 10

Target: Keratin 10 (KRT10)

Alternative Name: KRT10 / Cytokeratin 10

Background: This mAb recognizes a protein of 56.5  kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation, it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.